Oxygenta Pharmaceutical Ltd — Important, 27-07-2026: Company Update

Oxygenta Pharmaceutical Limited's board has approved the financial results for the quarter ended June 30, 2026. The company reported total revenue of ₹37.02 Cr and a net loss of ₹2.10 Cr for the quarter. The board also appointed M/s. PCR & Associates as Cost Auditors for FY 2026-27 and re-constituted its POSH Committee. The Annual General Meeting for FY 2025-26 is scheduled for August 21, 2026, via virtual means. Additionally, during the quarter, the company availed financial assistance of ¥399 lakhs under the government's Emergency Credit Line Guarantee Scheme (ECLGS).